Introduction {#s1}
============

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival following diagnosis of only 3 years.[@R1] Nintedanib has been shown to slow progression of IPF in the Phase II TOMORROW[@R3] and Phase III INPULSIS trials.[@R4]

Period 1 of the TOMORROW trial (NCT00514683) was a randomised, placebo-controlled, 52-week trial of four doses of nintedanib.[@R3] Compared with placebo, nintedanib 150 mg twice daily was associated with a reduced annual rate of decline in FVC and a lower incidence of acute exacerbations.[@R3] Diarrhoea was the most frequent adverse event.[@R3]

Patients who completed 52 weeks' treatment in TOMORROW period 1 continued treatment in a blinded phase (period 2), until the last patient had completed 52 weeks' treatment in period 1. Patients who completed period 2 could continue/start nintedanib in an open-label extension trial (NCT01170065).

Here we present efficacy and safety data from TOMORROW periods 1 and 2 and the open-label extension.

Methods {#s2}
=======

Online [supplementary figure 1](#SP3){ref-type="supplementary-material"} shows the design of TOMORROW periods 1 and 2 and the extension. The inclusion criteria for period 1 have been described.[@R3]
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###### Supplementary Figure 1

Data from patients randomised to nintedanib 150 mg twice daily (the recommended dose of nintedanib in IPF)[@R5] or placebo in period 1 are presented. The 'comparator group' presented comprises patients who received placebo in period 1, nintedanib 50 mg once daily in period 2, and nintedanib at a range of doses between 50 mg once daily and 150 mg twice daily in the extension.

All endpoints were exploratory and analysed in patients who received ≥1 dose of study drug in TOMORROW period 1. Acute exacerbations were defined as in TOMORROW period 1.[@R3] Safety was assessed via clinical and laboratory evaluation and recording of adverse events.

The annual rate of decline in FVC was estimated using a mixed model for repeated measures with fixed effects for treatment by time, gender by height, and gender by age, random effects for patient and patient by time and a variance component variance-covariance matrix. Kaplan-Meier estimates for time to first acute exacerbation and time to death were calculated based on data collected after randomisation. Time to death was analysed using a Cox proportional hazard model adjusted for age, gender and height. Analyses were descriptive with no formal statistical comparisons between groups.

Both trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonised Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonisation and were approved by local authorities. Informed consent was obtained from all participants.

Results {#s3}
=======

Patient characteristics at the start of period 1 were comparable across treatment groups (online [supplementary table 1](#SP2){ref-type="supplementary-material"}). Of 428 patients treated in period 1, a total of 286 entered period 2, and 198 entered the extension, including 35 in the nintedanib 150 mg twice daily group and 37 in the comparator group (35 of whom increased dose to nintedanib 150 mg twice daily) (online [supplementary figure 2](#SP4){ref-type="supplementary-material"} and [supplementary table 2](#SP2){ref-type="supplementary-material"}). Online [supplementary table 3](#SP2){ref-type="supplementary-material"} shows patient characteristics at entry into the extension. Mean (SD) total exposure was 27.6 (26.5) months for nintedanib and 28.1 (23.1) months for comparator (online [supplementary table 4](#SP2){ref-type="supplementary-material"}). Online [supplementary table 5](#SP2){ref-type="supplementary-material"} shows exposure by trial and treatment.
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###### Supplementary Table 1
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###### Supplementary Figure 2

The adjusted annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) for nintedanib and −189.7 mL/year (95% CI −229.8 to −149.6) for comparator ([figure 1A](#F1){ref-type="fig"}). The proportion of patients with ≥1 acute exacerbation was 12.9% for nintedanib and 25.9% for comparator. Based on analyses of time to first acute exacerbation, the probability of having an acute exacerbation was 30.5% with nintedanib and 48.3% with comparator ([figure 1B](#F1){ref-type="fig"}). Overall, 22 patients (25.9%) died in the nintedanib group and 34 (40.0%) died in the comparator group ([figure 1C](#F1){ref-type="fig"}). Further efficacy analyses are presented in the online supplementary material. [Table 1](#T1){ref-type="table"} shows a summary of adverse events.

![Annual rate of decline in FVC (A), Kaplan-Meier estimate of time to first acute exacerbation (B) and Kaplan-Meier estimate of time to death (C) over TOMORROW periods 1 and 2 and the open-label extension trial. Patients in the comparator group received placebo in period 1 of the TOMORROW trial and nintedanib 50 mg once daily in period 2. Patients entered the extension trial on the dose that they were receiving at the end of period 2, but had the option to increase dose to nintedanib 150 mg twice daily. Dose reduction from 150 mg twice daily to 100 mg twice daily and treatment interruption were permitted for the management of adverse events.](thoraxjnl-2016-209701f01){#F1}

###### 

Adverse events over TOMORROW periods 1 and 2 and the open-label extension trial by MedDRA preferred term

                                                           Nintedanib 150 mg twice daily (n=85)   Comparator (n=85)
  -------------------------------------------------------- -------------------------------------- -------------------
  Any adverse event(s)                                     84 (98.8)                              83 (97.6)
  Most frequent adverse events\*                                                                  
   Diarrhoea                                               63 (74.1)                              34 (40.0)
   Progression of IPF†                                     21 (24.7)                              27 (31.8)
   Nausea                                                  23 (27.1)                              18 (21.2)
   Cough                                                   14 (16.5)                              24 (28.2)
   Nasopharyngitis                                         14 (16.5)                              18 (21.2)
   Bronchitis                                              13 (15.3)                              19 (22.4)
   Dyspnoea                                                10 (11.8)                              20 (23.5)
   Vomiting                                                16 (18.8)                              11 (12.9)
   Weight decreased                                        15 (17.6)                              11 (12.9)
   Upper respiratory tract infection                       10 (11.8)                              15 (17.6)
   Decreased appetite                                      14 (16.5)                              6 (7.1)
   Pneumonia                                               4 (4.7)                                13 (15.3)
  Severe adverse event(s)‡                                 41 (48.2)                              50 (58.8)
  Serious adverse event(s)§                                47 (55.3)                              55 (64.7)
  Fatal adverse event(s)                                   12 (14.1)                              31 (36.5)
  Adverse event(s) leading to treatment discontinuation¶   48 (56.5)                              49 (57.6)
   Diarrhoea                                               15 (17.6)                              6 (7.1)
   Progression of IPF†                                     10 (11.8)                              12 (14.1)
   Nausea                                                  4 (4.7)                                2 (2.4)
   Abdominal pain                                          3 (3.5)                                0 (0.0)
   Weight decreased                                        3 (3.5)                                1 (1.2)
   Pneumonia                                               0 (0.0)                                4 (4.7)

Patients in the comparator group received placebo in TOMORROW period 1 and nintedanib 50 mg once daily in period 2. Patients entered the extension trial on the dose that they were receiving at the end of period 2, but had the option to increase dose to nintedanib 150 mg twice daily. Dose reduction from 150 mg twice daily to 100 mg twice daily and treatment interruption were permitted for the management of adverse events.

\*Adverse events reported by \>15% of patients in either nintedanib 150 mg twice daily or comparator group.

†Corresponds to MedDRA term 'IPF,' which included disease worsening and IPF exacerbations.

‡Event that was incapacitating or that caused an inability to work or to perform usual activities.

§Event that resulted in death, was immediately life threatening, resulted in persistent or clinically significant disability or incapacity, required or prolonged hospitalisation, was related to a congenital anomaly or birth defect, or was deemed serious for any other reason.

¶Adverse events leading to treatment discontinuation in \>3% of patients in either nintedanib 150 mg twice daily or comparator group. 'Cardiac disorder adverse events' (defined according to the MedDRA system organ class) were reported in 19 patients (22.4%) in the nintedanib 150 mg twice daily group and 18 patients (21.2%) in the comparator group.

IPF, idiopathic pulmonary fibrosis; MedDRA, Medical Dictionary for Regulatory Activities.

Discussion {#s4}
==========

In period 1 of the TOMORROW trial, nintedanib 150 mg twice daily was associated with a reduced rate of decline in FVC and fewer acute exacerbations versus placebo over 52 weeks.[@R3] Our analyses suggest that the efficacy of nintedanib 150 mg twice daily was maintained beyond 52 weeks. The small difference in FVC decline over TOMORROW periods 1 and 2 and the extension between the nintedanib 150 mg twice daily and comparator groups was not unexpected, as most patients in the comparator group received nintedanib 150 mg twice daily in the extension.

The annual rate of decline in FVC in the nintedanib group reported here is similar to that observed in the nintedanib 150 mg twice daily group in the Phase III INPULSIS trials (--113.6 mL/year).[@R4] In a pooled analysis of data from 1231 patients in TOMORROW period 1 and the INPULSIS trials, the annual rate of decline in FVC was −112.4 mL/year with nintedanib 150 mg twice daily and −223.3 mL/year with placebo (difference 110.9 mL/year (95% CI 78.5 to 143.3); p\<0.0001).[@R7]

Consistent with our analyses, in the pooled analysis of data from TOMORROW period 1 and the INPULSIS trials, nintedanib was associated with a significant reduction in the risk of acute exacerbation (HR 0.53 (95% CI 0.34 to 0.83); p=0.0047) and a numerical reduction in the risk of all-cause mortality (HR 0.70 (95% CI 0.46 to 1.08); p=0.0954).[@R7]

No relevant changes in the safety and tolerability of nintedanib were identified in our analysis of long-term data. A similar adverse event profile has been observed in INPULSIS-ON, the open-label extension of the INPULSIS trials.[@R8]

Limitations of our analyses include switches in treatments and doses that prevented statistical comparisons being made between groups; the lack of a true placebo group; and the potential for selection bias in patients who continued into the extension. Our analyses excluded patients who died or were unable to enter the extension due to disease progression. The small patient numbers available for analyses beyond period 1 means these results may underestimate the rate of FVC decline, particularly in the comparator group, in which most patients received nintedanib 150 mg twice daily in the extension.

In conclusion, results from the TOMORROW trial and its open-label extension support an effect of nintedanib on slowing the progression of IPF beyond 52 weeks. No new safety signals were identified with up to 86 months of treatment.
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